Vertex Pharmaceuticals, Inc (VRTX) receives a Sector outperform rating from Scotiabank

Samantha Gray

In a filing, Vertex Pharmaceuticals, Inc revealed its Director JEFFREY M LEIDEN acquired Company’s shares for reported $23.29 million on Nov 14 ’25. In the deal valued at $434.52 per share,53,604 shares were bought.

Then, JEFFREY M LEIDEN bought 19,688 shares, generating $8,548,333 in total proceeds.

Before that, Biller Jonathan sold 694 shares. Vertex Pharmaceuticals, Inc shares valued at $280,522 were divested by the EVP and Chief Legal Officer at a price of $404.21 per share. As a result of the transaction, Biller Jonathan now holds 15,653 shares, worth roughly $6.84 million.

Scotiabank initiated its Vertex Pharmaceuticals, Inc [VRTX] rating to a Sector outperform in a research note published on November 13, 2025; the price target was $495. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who increased its forecast for the stock in late September from “a Market perform” to “an Outperform”. Raymond James began covering VRTX with “Mkt perform” recommendation on September 03, 2025. Wells Fargo revised its rating on August 06, 2025. It rated VRTX as “an Overweight” which previously was an “an Equal weight”.

Price Performance Review of VRTX

On Friday, Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] saw its stock jump 0.61% to $437.15. Over the last five days, the stock has gained 6.76%. Vertex Pharmaceuticals, Inc shares have fallen nearly -10.79% since the year began. Nevertheless, the stocks have risen 8.55% over the past one year. While a 52-week high of $519.68 was reached on 03/14/25, a 52-week low of $362.50 was recorded on 08/11/25.

Levels Of Support And Resistance For VRTX Stock

The 24-hour chart illustrates a support level at 433.14, which if violated will result in even more drops to 429.13. On the upside, there is a resistance level at 441.69. A further resistance level may holdings at 446.23.

How much short interest is there in Vertex Pharmaceuticals, Inc?

A steep rise in short interest was recorded in Vertex Pharmaceuticals, Inc stocks on 2025-10-31, growing by 0.57 million shares to a total of 4.13 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 3.56 million shares. There was a rise of 13.91%, which implies that there is a positive sentiment for the stock.

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.